Regular analgesic use and risk of multiple myeloma

Kirsten B. Moysich, Mathew R. Bonner, Gregory P. Beehler, James R. Marshall, Ravi J. Menezes, Julie A. Baker, Joli R. Weiss, Asher A Chanan Khan

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but to date no previous research has focused on the role of analgesics in the etiology of multiple myeloma (MM). We conducted a hospital-based case-control study of 117 patients with primary, incident MM and 483 age and residence matched controls without benign or malignant neoplasms. All participants received medical services at Roswell Park Cancer Institute in Buffalo, NY, and completed a comprehensive epidemiological questionnaire. Participants who reported analgesic use at least once a week for at least 6 months were classified as regular users; individuals who did not use analgesics regularly served as the reference group throughout the analyses. We used unconditional logistic regression analyses to compute crude and adjusted odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Compared to non-users, regular aspirin users were not at reduced risk of MM (adjusted OR = 0.99; 95% CI 0.65-1.49), nor were participants with the highest frequency or duration of aspirin use. A significant risk elevation was found for participants who were regular acetaminophen users (adjusted OR = 2.95; 95% CI 1.72-5.08). Further, marked increases in risk of MM were noted with both greater frequency (>7 tablets weekly; adjusted OR = 4.36; 95% CI 1.70-11.2) and greater duration (>10 years; adjusted OR = 3.26; 95% CI 1.52-7.02) of acetaminophen use. We observed no evidence of a chemoprotective effect of aspirin on MM risk, but observed significant risk elevations with various measures of acetaminophen use. Our results warrant further investigation in population-based case-control and cohort studies and should be interpreted with caution in light of the limited sample size and biases inherent in hospital-based studies.

Original languageEnglish (US)
Pages (from-to)547-551
Number of pages5
JournalLeukemia Research
Volume31
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Multiple Myeloma
Analgesics
Odds Ratio
Confidence Intervals
Acetaminophen
Aspirin
Case-Control Studies
Neoplasms
Buffaloes
Chemoprevention
Sample Size
Tablets
Cohort Studies
Logistic Models
Regression Analysis
Research
Population

Keywords

  • Analgesic use
  • Case-control design
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Moysich, K. B., Bonner, M. R., Beehler, G. P., Marshall, J. R., Menezes, R. J., Baker, J. A., ... Chanan Khan, A. A. (2007). Regular analgesic use and risk of multiple myeloma. Leukemia Research, 31(4), 547-551. https://doi.org/10.1016/j.leukres.2006.07.027

Regular analgesic use and risk of multiple myeloma. / Moysich, Kirsten B.; Bonner, Mathew R.; Beehler, Gregory P.; Marshall, James R.; Menezes, Ravi J.; Baker, Julie A.; Weiss, Joli R.; Chanan Khan, Asher A.

In: Leukemia Research, Vol. 31, No. 4, 04.2007, p. 547-551.

Research output: Contribution to journalArticle

Moysich, KB, Bonner, MR, Beehler, GP, Marshall, JR, Menezes, RJ, Baker, JA, Weiss, JR & Chanan Khan, AA 2007, 'Regular analgesic use and risk of multiple myeloma', Leukemia Research, vol. 31, no. 4, pp. 547-551. https://doi.org/10.1016/j.leukres.2006.07.027
Moysich KB, Bonner MR, Beehler GP, Marshall JR, Menezes RJ, Baker JA et al. Regular analgesic use and risk of multiple myeloma. Leukemia Research. 2007 Apr;31(4):547-551. https://doi.org/10.1016/j.leukres.2006.07.027
Moysich, Kirsten B. ; Bonner, Mathew R. ; Beehler, Gregory P. ; Marshall, James R. ; Menezes, Ravi J. ; Baker, Julie A. ; Weiss, Joli R. ; Chanan Khan, Asher A. / Regular analgesic use and risk of multiple myeloma. In: Leukemia Research. 2007 ; Vol. 31, No. 4. pp. 547-551.
@article{45e6fc3887bc4ffabc2bdbcde0b5dd9c,
title = "Regular analgesic use and risk of multiple myeloma",
abstract = "Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but to date no previous research has focused on the role of analgesics in the etiology of multiple myeloma (MM). We conducted a hospital-based case-control study of 117 patients with primary, incident MM and 483 age and residence matched controls without benign or malignant neoplasms. All participants received medical services at Roswell Park Cancer Institute in Buffalo, NY, and completed a comprehensive epidemiological questionnaire. Participants who reported analgesic use at least once a week for at least 6 months were classified as regular users; individuals who did not use analgesics regularly served as the reference group throughout the analyses. We used unconditional logistic regression analyses to compute crude and adjusted odds ratios (ORs) with corresponding 95{\%} confidence intervals (CIs). Compared to non-users, regular aspirin users were not at reduced risk of MM (adjusted OR = 0.99; 95{\%} CI 0.65-1.49), nor were participants with the highest frequency or duration of aspirin use. A significant risk elevation was found for participants who were regular acetaminophen users (adjusted OR = 2.95; 95{\%} CI 1.72-5.08). Further, marked increases in risk of MM were noted with both greater frequency (>7 tablets weekly; adjusted OR = 4.36; 95{\%} CI 1.70-11.2) and greater duration (>10 years; adjusted OR = 3.26; 95{\%} CI 1.52-7.02) of acetaminophen use. We observed no evidence of a chemoprotective effect of aspirin on MM risk, but observed significant risk elevations with various measures of acetaminophen use. Our results warrant further investigation in population-based case-control and cohort studies and should be interpreted with caution in light of the limited sample size and biases inherent in hospital-based studies.",
keywords = "Analgesic use, Case-control design, Multiple myeloma",
author = "Moysich, {Kirsten B.} and Bonner, {Mathew R.} and Beehler, {Gregory P.} and Marshall, {James R.} and Menezes, {Ravi J.} and Baker, {Julie A.} and Weiss, {Joli R.} and {Chanan Khan}, {Asher A}",
year = "2007",
month = "4",
doi = "10.1016/j.leukres.2006.07.027",
language = "English (US)",
volume = "31",
pages = "547--551",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Regular analgesic use and risk of multiple myeloma

AU - Moysich, Kirsten B.

AU - Bonner, Mathew R.

AU - Beehler, Gregory P.

AU - Marshall, James R.

AU - Menezes, Ravi J.

AU - Baker, Julie A.

AU - Weiss, Joli R.

AU - Chanan Khan, Asher A

PY - 2007/4

Y1 - 2007/4

N2 - Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but to date no previous research has focused on the role of analgesics in the etiology of multiple myeloma (MM). We conducted a hospital-based case-control study of 117 patients with primary, incident MM and 483 age and residence matched controls without benign or malignant neoplasms. All participants received medical services at Roswell Park Cancer Institute in Buffalo, NY, and completed a comprehensive epidemiological questionnaire. Participants who reported analgesic use at least once a week for at least 6 months were classified as regular users; individuals who did not use analgesics regularly served as the reference group throughout the analyses. We used unconditional logistic regression analyses to compute crude and adjusted odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Compared to non-users, regular aspirin users were not at reduced risk of MM (adjusted OR = 0.99; 95% CI 0.65-1.49), nor were participants with the highest frequency or duration of aspirin use. A significant risk elevation was found for participants who were regular acetaminophen users (adjusted OR = 2.95; 95% CI 1.72-5.08). Further, marked increases in risk of MM were noted with both greater frequency (>7 tablets weekly; adjusted OR = 4.36; 95% CI 1.70-11.2) and greater duration (>10 years; adjusted OR = 3.26; 95% CI 1.52-7.02) of acetaminophen use. We observed no evidence of a chemoprotective effect of aspirin on MM risk, but observed significant risk elevations with various measures of acetaminophen use. Our results warrant further investigation in population-based case-control and cohort studies and should be interpreted with caution in light of the limited sample size and biases inherent in hospital-based studies.

AB - Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but to date no previous research has focused on the role of analgesics in the etiology of multiple myeloma (MM). We conducted a hospital-based case-control study of 117 patients with primary, incident MM and 483 age and residence matched controls without benign or malignant neoplasms. All participants received medical services at Roswell Park Cancer Institute in Buffalo, NY, and completed a comprehensive epidemiological questionnaire. Participants who reported analgesic use at least once a week for at least 6 months were classified as regular users; individuals who did not use analgesics regularly served as the reference group throughout the analyses. We used unconditional logistic regression analyses to compute crude and adjusted odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Compared to non-users, regular aspirin users were not at reduced risk of MM (adjusted OR = 0.99; 95% CI 0.65-1.49), nor were participants with the highest frequency or duration of aspirin use. A significant risk elevation was found for participants who were regular acetaminophen users (adjusted OR = 2.95; 95% CI 1.72-5.08). Further, marked increases in risk of MM were noted with both greater frequency (>7 tablets weekly; adjusted OR = 4.36; 95% CI 1.70-11.2) and greater duration (>10 years; adjusted OR = 3.26; 95% CI 1.52-7.02) of acetaminophen use. We observed no evidence of a chemoprotective effect of aspirin on MM risk, but observed significant risk elevations with various measures of acetaminophen use. Our results warrant further investigation in population-based case-control and cohort studies and should be interpreted with caution in light of the limited sample size and biases inherent in hospital-based studies.

KW - Analgesic use

KW - Case-control design

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=33846658275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846658275&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.07.027

DO - 10.1016/j.leukres.2006.07.027

M3 - Article

C2 - 16962170

AN - SCOPUS:33846658275

VL - 31

SP - 547

EP - 551

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 4

ER -